SRR8392886
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- ALLOGRAFT_REJECTION+0.480
- COAGULATION+0.440
- INFLAMMATORY_RESPONSE+0.440
- INTERFERON_GAMMA_RESPONSE+0.420
- IL6_JAK_STAT3_SIGNALING+0.390
- INTERFERON_ALPHA_RESPONSE+0.380
- KRAS_SIGNALING_UP+0.380
- MYOGENESIS+0.340
- KRAS_SIGNALING_DN+0.330
Top 10 suppressed
- MYC_TARGETS_V1-0.700
- E2F_TARGETS-0.580
- MYC_TARGETS_V2-0.560
- G2M_CHECKPOINT-0.540
- OXIDATIVE_PHOSPHORYLATION-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- PROTEIN_SECRETION-0.490
- MTORC1_SIGNALING-0.480
- DNA_REPAIR-0.470
- MITOTIC_SPINDLE-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013478 | — | cohortMD2 | 0.952 |
| 2 | SRR598894 | GTEX | — | 0.952 |
| 3 | TCGA-55-8510-01A-11R-2403-07 | — | cohortA1 | 0.952 |
| 4 | TCGA-22-1005-01A-01R-0692-07 | — | cohortMD2 | 0.949 |
| 5 | SRR601201 | GTEX | — | 0.941 |
| 6 | 2d8d97e6-b599-4444-8e11-73adb55be0be | — | — | 0.941 |
| 7 | MDT-AP-1215 | Med | Medulloblastoma | 0.940 |
| 8 | SRR1468141 | GTEX | — | 0.940 |
| 9 | SRR1394297 | GTEX | — | 0.939 |
| 10 | SRR1331289 | GTEX | — | 0.939 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.040 | Inavolisib | — uncovered |